Odyssey Therapeutics (ODTX) Corporate presentation summary

Unmet needs in autoimmune and inflammatory diseases

• Durable remission rates for autoimmune diseases remain low despite decades of new therapies, with most patients failing to achieve long-term disease control.

• Current therapies often target downstream immune responses, leading to limited efficacy and persistent safety concerns.

• Patients require therapies that provide deeper, more durable disease modification with improved safety and tolerability.

Strategic approach and leadership

• Focus on first-in-class targets and validated pathways, with a modality-agnostic portfolio targeting large I&I indications.

• Multiple programs are at the development candidate stage or later, supported by an experienced leadership team and board.

• Efficient capital allocation with $464M in cash as of March 31, 2026, and a lean, agile structure for rapid execution.

Pipeline and clinical milestones

• Lead program OD-001 (RIPK2 inhibitor) targets IBD, with phase 2a monotherapy data showing a 27% clinical remission rate in moderate-to-severe UC.

• OD-002 (SLC15A4 inhibitor) and OD-003 (TNFR2 agonist) address B cell-mediated and Treg-related diseases, respectively, with IND-enabling studies ongoing.

• Key milestones include multiple phase 2 readouts for OD-001 and phase 1/2 initiation for OD-002 through 2028.